Multilisa® IVD Products

Our diagnostic offering

Diagnostics (Dx) and companion diagnostics (CDx) are extremely valuable tools for the improvement of patient treatment via more personalized and targeted therapeutic strategies. Protagen is applying its proprietary biomarker discovery technology, SeroTag®, to develop novel tests in the areas of autoimmune disease and immuno-oncology.

Through the detection and application of autoantibody signatures in patient serum, Protagen’s assays can accurately diagnose and profile individuals suffering from chronic and debilitating autoimmune conditions, enabling early detection and diagnosis.

Discover our pipeline of diagnostic tests from biomarker discovery and development to market-ready, CE-approved IVD products, across a range of autoimmune indications with unmet diagnostic and therapeutic needs. Proprietary biomarkers identified and validated within this process can also be licensed from Protagen by partners to support commercial diagnostic development efforts.

Multilisa SSc

Systemic sclerosis (SSc; also termed scleroderma) is a rare, complex, multi-organ autoimmune disease which manifests as progressive fibrosis of the skin and internal organs and has a high unmet diagnostic need.

Multilisa SLE

Utilizing 5 newly-discovered, proprietary biomarkers alongside established auto-antigens, Protagen has created more sensitive and specific diagnostic tests.

Multilisa RA

Protagen has focused on identifying novel biomarkers to reliably identify RF/ACPA negative RA patients, a group currently under supported with serum-based IVD tests.

Product Development Pipeline

Using its SeroTag® platform, Protagen is uniquely positioned to combine the largest global human protein library with the high-throughput identification of disease-specific markers in patient samples to develop novel diagnostics.